Companies who receive scientific advice from our NICE Advice service may experience a faster path to guidance publication, a study has found. The research, which will be presented to delegates at the ...

Are you facing challenges in quickly bringing new healthtech products to market? The NHS is a large and complex system and ...

Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia TA1013 23 October 2024 23 October 2024 ...

We have also today published a new discussion aid to support shared decision making about HRT, focusing on the key risks and benefits to consider. The guideline clarifies that whilst HRT has some ...

We use tools such as Google Analytics, Hotjar, Google Optimize and Loop11 to help us anonymously measure how you use our websites. This allows us to make improvements based on our users' needs.

The London School of Economics and Political Science (LSE) have joined forces with NICE to offer a unique solution - the Executive MSc in Healthcare Decision-Making.

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

Your organisation needs to be registered as a stakeholder before we can accept comments. Not eligible? Contact the stakeholder organisation that most closely represents your interests and pass your ...

There is a simple discount patient access scheme for avapritinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non‑NHS organisations can contact ...

Suggested remit: To appraise the clinical and cost effectiveness of inhaled treprostinil within its marketing authorisation for treating pulmonary hypertension caused by interstitial lung disease.

A list of downloadable documents created during development.